3 results
Approved WMORecruiting
.
Approved WMOCompleted
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
Approved WMORecruiting
Main objective- to investigate the effect of alfacalcidol on the treatment of secondary hyperparathyroidism in patients after RYGB Secondary objectives: - to investigate bone turnover and changes in BMD in relation to secondary hyperparathyroidism…